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FLT3-ITD mutations are prevalent mutations in acute myeloid leukaemia (AML).
PRL-3, a metastasis-associated phosphatase, is a downstream target of FLT3-ITD.
This study investigates the regulation and function of PRL-3 in leukaemia cell
lines and AML patients associated with FLT3-ITD mutations. PRL-3 expression is
upregulated by the FLT3-STAT5 signalling pathway in leukaemia cells, leading an
activation of AP-1 transcription factors via ERK and JNK pathways. PRL-3-
depleted AML cells showed a significant decrease in cell growth. Clinically, high
PRL-3 mRNA expression was associated with FLT3-ITD mutations in four
independent AML datasets with 1158 patients. Multivariable Cox-regression
analysis on our Cohort 1 with 221 patients identified PRL-3 as a novel prognostic
marker independent of other clinical parameters. Kaplan–Meier analysis showed
high PRL-3 mRNA expression was significantly associated with poorer survival
among 491 patients with normal karyotype. Targeting PRL-3 reversed the
oncogenic effects in FLT3-ITD AMLmodels in vitro and in vivo. Herein, we suggest
that PRL-3 could serve as a prognostic marker to predict poorer survival and as a
promising novel therapeutic target for AML patients.
INTRODUCTION
Acute myeloid leukaemia (AML) is characterized by a block in
differentiation and uncontrolled proliferation of malignant
clones of immature myeloid cells (Lowenberg et al, 1999).
Because of the high heterogeneity of acquired mutations
occurring through unknown mechanisms, therapeutic
approaches have limited efﬁcacies and clinical outcomes of
AML patients are poor (Sternberg & Licht, 2005). Activating
mutations in fms‐like tyrosine kinase‐3 (FLT3) represent one of
the more frequent genetic alterations in AML (Rockova
et al, 2011), involving internal tandem duplication (ITD) in
the juxtamembrane (JM) domain of FLT3 (Nakao et al, 1996).
The constitutive activation of FLT3‐ITD leads to elevated and
sustained activation of multiple downstream signalling path-
ways, ultimately resulting in the transformation of haemato-
poietic cells to growth factor‐independent proliferation (Mizuki
et al, 2000). Due to pro‐proliferative and anti‐apoptotic roles in
AML cells, activating mutations in FLT3 have been proposed as
promising molecular targets for the treatment of AML. However,
despite advances in drug discovery and our understanding of the
molecular mechanism of FLT3 mutations, clinical trials with
FLT3 inhibitors so far have shown limited success due to drug
resistance and poor clinical response (Weisberg et al, 2010). This
suggests that understanding of the underlying mechanism of
FLT3 mutations may help in the development of better
therapeutic strategies.
PRL‐3, a phosphatase that we identiﬁed in 1998 (Zeng
et al, 1998), was recently found as part of a core gene signature
that is uniquely down‐regulated by combination therapy of
(1) Institute of Molecular and Cell Biology, ASTAR (Agency for Science,
Technology and Research), Singapore
(2) Cancer Science Institute of Singapore, National University of Singapore,
Singapore
(3) Department of Hematology, Erasmus University Medical Center Rotter-
dam, Rotterdam, The Netherlands
(4) Centre for Cancer Research and Cell Biology, Queen’s University Belfast,
Northern Ireland, UK
(5) Department of Haematology-Oncology, National University Cancer
Institute, Singapore
(6) Department of Medicine, Yong Loo Lin School of Medicine, National
University of Singapore, Singapore
(7) Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA
(8) Department of Biochemistry, Yong Loo Lin School of Medicine, National
University of Singapore, Singapore
*Corresponding author: Tel: þ65 6586 9664; Fax: þ65 6779 1117;
E-mail: mcbzengq@imcb.a-star.edu.sg
**Corresponding author: Tel: þ44 28 9097 2786;
E-mail: k.mills@qub.ac.uk
Research Article TRANSPARENT
PROCESS
OPEN
ACCESSOncogenic roles of PRL‐3 in AML
 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. This is an open access article under
the terms of the Creative Commons Attribution License (CC BY 3.0), which permits use, distribution and reproduction
in any medium, provided the original work is properly cited. EMBO Mol Med (2013) 5, 1351–1366 1351
Linifanib (ABT‐869, a FLT3 inhibitor) and suberoylanilide
hydroxanic acid (SAHA, a histone deacetylase inhibitor) in
AML cells (Zhou et al, 2011). Intriguingly, PRL‐3 was recently
reported as a possible downstream target of FLT3‐ITD signalling,
with a potential role in drug resistance of leukaemia cells (Zhou
et al, 2011), indicating that PRL‐3 expression levels could be an
important factor contributing to the outcomes of the AML
treatments. Furthermore, the Gene Expression Atlas (http://
www.ebi.ac.uk/gxa/gene/ENSG00000184489) showed that the
expression level of PRL‐3 was the highest in chronic myeloid
leukaemia (CML) among 950 human cancer cell lines covering
32 different types of cancers (Dataset code: E‐MTAB‐37),
suggesting a potential role of PRL‐3 in CML pathogenesis as well.
Previously, PRL‐3 was ﬁrst discovered to be speciﬁcally up‐
regulated in metastatic colorectal cancer cells (Saha et al, 2001)
and subsequently reported to be associated with many other
types of cancer metastasis such as breast, liver and gastric
cancers (Bessette et al, 2008). Diverse roles of PRL‐3 in cancer
progression, including cell migration, invasion, proliferation,
angiogenesis and metastasis, have been highlighted in recent
reports that emphasize the importance of PRL‐3 in tumouri-
genesis (Al‐Aidaroos & Zeng, 2010; Liang et al, 2007). Increas-
ingly, PRL‐3 has emerged as a potentially useful biomarker for
cancer prognosis, particularly the prediction of cancermetastasis
(Matsukawa et al, 2010; Ren et al, 2009).
In this report, we investigated the role of PRL‐3 in FLT3‐ITD
positive AML cells and patient samples. We describe the
regulation of PRL‐3 by a FLT3‐Src‐STAT5 signalling in AML cells.
PRL‐3 expression correlated positively with FLT3‐ITD mutation
in AML patients. PRL‐3 overexpression was associated with the
activation of c‐Jun proto‐oncogene and cell growth. Finally,
we describe the clinical relationship between elevated PRL‐3
expression and shorter overall survival in AML patients, and
characterize elevated PRL‐3 expression as an independent
prognostic marker for AML. A critical role of PRL‐3 in
leukaemogenesis was revealed using PRL‐3‐targeted immuno-
therapy in a leukaemic mouse model, suggesting that PRL‐3
could be a potential therapeutic target for AML.
RESULTS
PRL‐3 is frequently up‐regulated in AML patients with
FLT3‐ITD mutations
To investigate a correlation between PRL‐3 overexpression and
FLT3‐ITD mutations, 19 bone marrow samples from AML
patients with or without FLT3‐ITD mutations were analysed.
The incidence of PRL‐3 upregulation in AML was found to be
highly associated with FLT3‐ITD mutation (ﬁve out of seven
cases, 71.4%), compared with only 3 out of 12 (25%) cases
without FLT3‐ITD mutation (Fig 1A). Similarly, high PRL‐3
expression was observed in two FLT3‐ITD positive cell lines
(MOLM‐14 and MV4‐11; Fig 1A). Quantitative real‐time PCR
analysis of PRL‐3 mRNA from the same patients supported that
a higher PRL‐3 mRNA expression was associated with AML
patients with FLT3‐ITD mutations (Supporting Information
Fig S1). To extend this ﬁnding, we analysed our unpublished
Belfast/MILE dataset (Cohort 1), consisting of total 221 AML
patients. Among them, 101 patients with normal karyotype were
used to analyse the relationship between PRL‐3 expression level
and FLT3‐ITD mutation status. Only 10% of FLT3‐ITD negative
AML patients expressed ‘very highly’ PRL‐3 (Chi‐square test,
p ¼ 0.001), whereas over 40% of FLT3‐ITD positive patients
expressed ‘very highly’ PRL‐3 (black block, Fig 1B, a). Our
observation was further corroborated in three independent,
publicly available AML patient datasets (GSE1159 n ¼ 285,
GSE6891 n ¼ 521 and GSE15434 n ¼ 251), where PRL‐3
expression was consistently observed to be signiﬁcantly higher
in AML patients who were positive for FLT3‐ITD mutation
compared to those whowere negative for FLT3‐ITDmutations in
three independent datasets (Fig 1B, b–d; Chi‐square test;
p < 0.001). In summary, our analysis of four separate AML
patient cohorts show a strong association between FLT3‐ITD
mutations and high PRL‐3 expression in a total of 1158 AML
patients.
These results indicate that constitutive activation of FLT3
signalling might lead to PRL‐3 overexpression in AML patients.
To validate the clinical data, we either overexpressed or depleted
FLT3‐ITD in human myeloid leukaemia cell lines. Compared
with TF‐1 control cells (Fig 1C, lane 1), both MV4‐11 and
MOLM‐14 cell lines harbouring endogenous FLT3‐ITD mutations
and TF‐1 cell line over‐expressing exogenous FLT3‐ITD (TF1‐ITD)
had higher levels of PRL‐3 (Fig 1C, lanes 2–4). In contrast,
siRNA‐mediated depletion of FLT3 expression in MOLM‐14 and
MV4‐11 cells effectively suppressed PRL‐3 expression (Fig 1D).
Collectively, our results allude to a close relationship between
FLT3‐ITD mutation and elevated PRL‐3 expression in AML cells.
Constitutive activation of FLT3 enhances PRL‐3 expression
through Src‐STAT5 signalling pathway
To investigate if constitutively active FLT3 signalling was
involved in upregulation of PRL‐3 expression, we used FLT3
inhibitors to block FLT3 receptor activity and examined the
downstream signalling molecules of FLT3‐ITD mutation. Since
STAT5 was known to be a critical downstream target of FLT3‐
ITD (Mizuki et al, 2000), we tested STAT5 expression level after
treatment with FLT3‐speciﬁc inhibitors; PKC412 or CEP‐701
(Odgerel et al, 2007; Smith et al, 2004). The respective inhibitors
reduced phosphorylation of FLT3 and STAT5 in a dose
dependent manner and resulted in a corresponding decrease
in PRL‐3 protein levels in TF1‐ITD and MOLM‐14 cell lines
(Fig 2A). We next examined whether FLT3‐ITD‐induced PRL‐3
expression might be mediated by JAK or Src, two distinct
upstream activators of STAT5 (Robinson et al, 2005; Spieker-
mann et al, 2003). After treatment with FLT3 inhibitors, both
phospho‐ and total‐JAK2 levels were not affected (Fig 2B),
whereas the activated form of Src (pSrc Y416) was potently
down‐regulated after treatment. Importantly, Src inactivation
closely corresponded with a decrease of STAT5 phosphorylation
in a dose‐dependent manner (Fig 2B). To investigate the role of
Src‐mediated phosphorylation of STAT5 in FLT3‐ITD positive
AML cells, AML cells were treated with two distinct Src kinase
inhibitors, SU6656 and PP2 (Blake et al, 2000; Nam et al, 2002).
Src inhibition reduced both STAT5 phosphorylation and PRL‐3
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expression levels (Fig 2C), revealing a correlation between Src‐
mediated STAT5 phosphorylation and PRL‐3 expression.
STAT5 is a potent transcriptional regulator of PRL‐3 expression
To understand how PRL‐3 could be up‐regulated, the human
PRL‐3 promoter region was analysed by the Transcription Factor
Database (TRANSFAC) to predict possible transcription factor
binding sites (Wingender et al, 1996). The TRANSFAC program
identiﬁed a number of putative transcription factors binding sites
at the upstream promoter region of PRL‐3, including two STAT5
consensus binding sequence TTCN(3)GAA (Seidel et al, 1995;
Fig 3A). To evaluate the role of STAT5 as a transcriptional
regulator of PRL‐3, we designed two biotinylated probes, S1 and
S2, corresponding to these STAT5 binding sequences and
performed gel mobility shift assay (EMSA) using nuclear extracts
from either TF‐1 (PRL‐3 non‐expressing) or TF1‐ITD (PRL‐3
expressing) cells (Fig 1C, lanes 1, 4). Nuclear extracts from TF1‐
ITD cells exhibited a robust level of DNA binding activity
Figure 1. PRL‐3 mRNA levels are elevated in FLT3‐ITD‐positive AML samples.
A. RT-PCR analysis of PRL-3mRNA expression levels in 19 bonemarrow samples from AML patients either negative (ITD NEG; n ¼ 12) or positive (ITD POS; n ¼ 7)
for FLT3-ITD mutation. MOLM-14 and MV4-11 AML cell lines were used as FLT3-ITD positive controls. b-actin, loading control.
B. (a–d) Microarray data analysis of PRL-3 mRNA levels in FLT-ITD-positive (POS) or FLT3-ITD-negative (NEG) patients in four independent patient cohorts (total
n ¼ 1158). (a) Cohort 1 AML patient with normal karyotype (n ¼ 101, p ¼ 0.001). (b) GSE1159 AML patient cohort (n ¼ 285, p < 0.001). (c) GSE6891 AML
patient cohort (n ¼ 521, p < 0.001). (d) GSE15434 AML patient cohort (n ¼ 251, p < 0.001). Statistical differences between ITD-POS and ITD-NEG patients
were determined using Chi-square test. PRL-3 expression level is divided into four groups: very high, high, intermediate, low.
C. Western blot analysis of PRL-3 protein levels in four AML cell lines.
D. Western blot analysis of PRL-3 in MOLM-14 and MV4-11 cells upon siRNA-mediated knock-down of FLT3 expression. NS, control non-silencing siRNA. GAPDH,
loading control.
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speciﬁcally to probe S1 (5.4 kb) but not to probe S2 (18.4 kb)
while nuclear extracts from parental TF‐1 cells had no observable
DNA binding activity with probe S1 or S2 (Fig 3B). Unlabelled
competing oligonucleotides containing the STAT5 binding
sequence could efﬁciently displace the labelled probe during
the binding shift assay (Fig 3C). To further ensure the
involvement of STAT5 in this protein/DNA complex, streptavi-
din–agarose pull‐down assay was performed using biotinylated
probe S1. Consistent with the EMSA result, Western blot analysis
with STAT5 antibody conﬁrmed that STAT5 was the transcrip-
tion factor binding to the probe S1 in the complex (Fig 3D).
To further clarify the binding property of STAT5 to the
upstream region of PRL‐3 promoter, reporter assays were
carried out using co‐transfection of either STAT5A or STAT5B
expression vector together with pGL3 luciferase vectors
containing either the 5.4 kb upstream sequence of the
PRL‐3 promoter region or its sequential 50‐deletion constructs
(S1a, S1b, S1c and S1d; Fig 3E, left panel). Similar protein
Figure 2. PRL‐3 protein expression decreases upon FLT3 or Src inhibition in AML cell lines. TF1-ITD and MOLM-14 cells were incubated with various
concentrations of FLT3 inhibitors (PKC412, CEP-701) or Src inhibitors (SU6656, PP2) for 24 h. Whole cell lysates were subjected to Western blot analysis with
indicated antibodies. GAPDH, loading control.
A. (a–d) Western blot analysis of AML cells upon FLT3 inhibition. PKC412 and CEP-701 inhibited the phosphorylation of both FLT3 and STAT5 as well as PRL-3
protein levels in a dose-dependent manner in both TF1-ITD (a, b) and MOLM-14 (c, d) cells
B. (a–d) Western blot analysis of AML cells upon FLT3 inhibition. PKC412 and CEP-701 inhibited the phosphorylation of Src, but not JAK, in a dose-dependent
manner in both TF1-ITD (a, b) and MOLM-14 (c, d) cells.
C. (a, b) Western blot analysis of AML cells upon Src inhibition. SU6656 (a) and PP2 (b) inhibited the phosphorylation of Src and STAT5 as well as PRL-3 protein
levels in a dose-dependent manner in TF1-ITD cells.
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expression levels of transfected STAT5A or STAT5B are shown in
Supporting Information Fig S2. In TF‐1 cells, when STAT5A
expression vector was co‐transfected with reporter constructs
S1a–c, luciferase activities were increased three‐ to fourfold
relative to the S1d deletion construct, which lacked of STAT5
binding site (Fig 3E, black columns). Interestingly, co‐expression
of STAT5B with the reporter constructs showed no signiﬁcant
increase in reporter activity (Fig 3E, open columns), suggesting
that this activation could be speciﬁc for STAT5A but not for
STAT5B. To support the role of STAT5 as a key transcription
regulator of PRL‐3, STAT5 was depleted by siRNA knock‐down
approach in three AML cell lines; TF1‐ITD, MOLM‐14 and
MV4‐11. Silencing of STAT5 attenuated PRL‐3 mRNA (Fig 3F, a),
consequently, decreased in PRL‐3 protein expression levels
(Fig 3F, b). These results further enforced the positive regulation
of STAT5 on PRL‐3 expression.
Figure 3. STAT5A is a direct transcriptional regulator of PRL‐3 expression.
A. Two putative STAT5 binding sites (S1 and S2; DNA sequences illustrated) in a distal 50-flanking region of PRL-3, as predicted by TRANSFAC.
B. EMSA analysis using S1 and S2 biotinylated DNA probes (S1 and S2) incubated with nuclear extracts from either TF-1 or TF1-ITD cells. Arrow, shifted protein/
probe complex.
C. EMSA analysis as in (B) in the presence of 10-fold molar excess of unlabelled STAT5 competitor.
D. Western blot analysis of streptavidin–agarose pull-down fractions (unbound or bound) using probe S1.
E. Left panel: schematic diagram of a 5.4 kb upstream sequence of PRL-3 and its 50-sequential deletion sequence with luciferase reporter vector (pGL3-S1a,
S1b, S1c and S1d), respectively. Right panel: STAT5A or STAT5B expression vectors were co-transfected with PRL-3 luciferase reporter vector to TF-1 cells and
luciferase activity measured. Error bars represent the mean  SD from three independent experiments.
F. PRL-3 expression is down-regulated upon siRNA-mediated STAT5 depletion in AML cells. NS, control non-silencing siRNA. (a) Quantitative real time PCR
analysis of PRL-3mRNA level after knock-down of STAT5 gene, normalized to GAPDHmRNA. Statistical differences between two groups were determined using
Student’s t-test (mean  SD, n ¼ 3). p < 0.001 (for TF1-ITD); p ¼ 0.011 (for MOLM-14); p ¼ 0.038 (for MV4-11). (b) Western blot analysis of PRL-3
protein level after knock-down of STAT5 gene. GAPDH, loading control.
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Upregulation of PRL‐3 activates AP‐1 oncogenic transcription
factor through ERK and JNK cascades
PRL‐3 has been reported to play important roles in tumour
development (Guo et al, 2006; Matsukawa et al, 2010). Thus, we
investigated the molecular consequences of PRL‐3 overexpres-
sion on various oncogenic transcription factors, such as AP‐1, a
well‐known transcription factor driving tumourigenesis (Eferl &
Wagner, 2003). For this, we performed secreted alkaline
phosphatase (SEAP) assay with pAP1‐SEAP vector, which
contains the SEAP reporter gene under the control of AP‐1
promoter, using TF1‐PRL‐3 (TF‐1 cells overexpressing GFP‐
PRL‐3) and TF1‐GFP control cells. As shown in Fig 4A, TF1‐PRL‐3
cells displayed a >2.5‐fold increase in SEAP activity when
compared to the TF1‐GFP control cells, implying that PRL‐3
could induce AP‐1 expression. To investigate if this observation
from TF‐1 leukaemia cell line is applicable to solid tumour cell
lines, two colorectal carcinoma cell lines, DLD‐1 and HCT116,
were examined. Consistently, overexpression of PRL‐3 led to a
>6.5‐fold and >2.5‐fold increase in AP‐1 activity in DLD‐1 cells
and HCT116 cells, respectively (Supporting Information Fig S3).
Figure 4. PRL‐3 speciﬁcally activates c‐Jun through ERK and JNK signalling pathways.
A. SEAP reporter assay results measuring AP-1 activity in TF-1 cells overexpressing GFP (TF1-GFP) or GFP-PRL-3 (TF1-PRL-3). Error bars represent the mean  SD
from three independent experiments.
B. (a, b) PRL-3 specifically upregulates c-Jun but not c-Fos. (a) Western blot analysis of TF1-GFP, TF1-PRL-3 and TF1-ITD cells. (b) Western blot analysis after
knock-down of endogenous PRL-3 in TF1-ITD cells. GAPDH, loading control. NS, control non-silencing siRNA.
C. (a–d) PRL-3-mediated upregulation of c-Jun is dependent on ERK and JNK pathways. (a) Western blot analysis after knock-down of endogenous PRL-3 in TF1-
ITD and MOLM-14 cells. (b) Western blot analysis of TF1-GFP and TF1-PRL-3 cells. (c, d) Western blot analysis after knock-down of ERK1/2 or JNK in TF1-PRL-3
cells. GAPDH, loading control. NS, control non-silencing siRNA.
D. (a–c) MTS assay results reflecting numbers of viable TF1-PRL-3 cells after treatment with ERK-specific inhibitor (U0126), JNK-specific inhibitor (SP600125) or
general AP-1 inhibitor (curcumin) for the various time points. Error bars represent the mean  SD from three independent experiments.
Research Article www.embomolmed.org
Oncogenic roles of PRL‐3 in AML
1356  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2013) 5, 1351–1366
To further identify the activated AP‐1 complex, we performed
Western blot analysis against c‐Jun and c‐Fos protein, the two
key members of the AP‐1 complex. Compared to TF1‐GFP
control cells, c‐Junwas up‐regulated in both TF1‐PRL‐3 and TF1‐
ITD cells while c‐Fos was only detected in TF1‐ITD but not in
TF1‐PRL‐3 cells (Fig 4B, a), indicating that PRL‐3 preferentially
stimulates c‐Jun but not c‐Fos. This result was veriﬁed by knock‐
down of PRL‐3 in TF1‐ITD cells, which showed that the loss of
PRL‐3 reduced c‐Jun (but not c‐Fos) expression (Fig 4B, b). Since
MAP kinases are actively involved in the regulation of AP‐1
transcription factors (Zhang & Liu, 2002), we investigated
whether induction of c‐Jun might be a consequence of the
activation of MAP kinases (MEK/ERK or JNK). Depletion of
PRL‐3 decreased the phosphorylation of JNK and ERK, leading to
a subsequent loss of c‐Jun phosphorylation in TF1‐ITD and
MOLM‐14 cells (Fig 4C, a). In addition, overexpression of PRL‐3
induced ERK and JNK phosphorylation in TF1‐PRL‐3 cells
compared to TF1‐GFP cells (Fig 4C, b). These results suggest that
PRL‐3 acts through ERK and/or JNK cascades to activate
oncogenic c‐Jun. To further conﬁrm this, we knock‐downed
either ERK or JNK with respective siRNA in TF1‐PRL‐3 cells and
the results showed that depletion of either ERK (Fig 4C, c) or JNK
(Fig 4C, d) suppressed phosphorylation of c‐Jun.
Since c‐Jun is known to promote cell proliferation in various
cancers (Hui et al, 2007; Zhang et al, 2007), we then investigated
if activation of PRL‐3‐ERK/JNK‐c‐Jun pathway affect AML cell
growth. TF1‐PRL‐3 cells treated with MEK‐speciﬁc inhibitor
(U0126, 5 mM) or JNK‐speciﬁc inhibitor (SP600125, 5 mM)
showed around 50% reduction in cell number compared to
DMSO‐treated control cells at 72 h (Fig 4D, a and b). In addition,
treatment with 15 mM curcumin, a general inhibitor of AP‐1
family (Balasubramanian & Eckert, 2007; Wang et al, 2009),
decreased cell number to 50% of DMSO‐treated cells at 72 h
(Fig 4D, c).
PRL‐3 overexpression promotes cell growth and inhibits
apoptosis
To investigate the biological outcomes of PRL‐3 overexpression,
the gain of PRL‐3 function in TF‐1 cells was examined. TF‐1 is a
cytokine dependent cell line requiring supplementation of
cytokines such as IL‐3 or GM‐CSF in culture media to sustain
cell growth and survival (Lin et al, 2007). Without cytokine,
TF‐1‐GFP vector control cells grow poorly (Fig 5A) and showed a
22.8% sub‐G1 apoptotic population at 48 h time point (Fig 5B,
left panel). However, TF‐1 cells overexpressing PRL‐3 (TF1‐
PRL‐3 cells) became cytokine independent in term of cell growth
and cell number increased to around twofold of TF1‐GFP control
cells at the same time point (Fig 5A). Furthermore, as presented
in Fig 5B, TF1‐PRL‐3 cells had a much smaller sub‐G1 apoptotic
population (1.7%, Fig 5B, right panel) despite the lack of
Figure 5. PRL‐3 promotes growth and suppresses
apoptosis of TF‐1 leukaemia cells upon cytokine
deprivation.
A. Right panel: MTS assay results reflecting numbers
of viable TF1-GFP and TF1-PRL-3 cells after
culture in the absence of cytokines for various
durations. Error bars represent the mean  SD
from three independent experiments. Left panel:
Western blot analysis of TF1-GFP and TF1-PRL-3
cells. GAPDH, loading control.
B. Flow cytometry analysis of propidium iodide-
stained TF1-GFP and TF1-PRL-3 after 48 h culture
in the absence of cytokines. Note the difference in
sub-G1 peak/population, reflective of apoptotic
cells. Representative data from three independent
experiments are shown.
C. Left panel: flow cytometry analysis of annexin-V-
and 7-AAD-stained TF1-GFP and TF1-PRL-3 after
48 h culture in the absence of cytokines. The
percentage in the upper left quadrant indicates
the fraction of annexin-V-positive apoptotic cells
in the entire cell population analysed. Right panel:
quantitation of annexin-V-positive apoptotic
population in three independent experiments.
Statistical differences between two groups were
determined using Student’s t-test (mean  SD,
n ¼ 3, p ¼ 0.0012).
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cytokine supplementation. To study anti‐apoptotic activity of
PRL‐3 in the absence of cytokine supplementation, we
performed annexin‐V and 7‐aminoactinomycin D (7‐AAD)
staining followed by ﬂuorescence‐activated cell sorting (FACS)
analysis on TF1‐GFP versus TF1‐PRL‐3 cell lines. More apoptotic
population (31%) was observed in TF1‐GFP cells than in
TF1‐PRL‐3 cells (6.8%) after 48 h culture without cytokine
supplement (Fig 5C), suggesting that PRL‐3 might play an anti‐
apoptotic role and sustain the cell growth in TF1‐PRL‐3 AML
cells.
PRL‐3 depletion reduces cell growth
To investigate the loss of PRL‐3 function in AML cell lines, we
knocked down of PRL‐3 in two cytokine independent cell lines
(MOLM‐14 and MV4‐11) that highly express both endogenous
FLT3‐ITD and PRL‐3 (Fig 1C). After depletion of PRL‐3, cell
viability was assessed at various time points (Fig 6A, a and B, a).
Interestingly, silencing of PRL‐3 by siRNA resulted in reduced
cell number by 64.5% in MOLM‐14 cells and 66.7% in
MV4‐11 cells compared to their mock knock‐down cells at 48 h.
Furthermore, cell cycle analysis implied that the reduction in cell
number in PRL‐3‐ablated cells correlated with increasing G1 and
decreasing S phase populations ("G1/S#) in MOLM‐14 and
MV4‐11 cell lines. The ratio of G1/S populationswas 46.6%/41.1%
in MOLM‐14 mock knock‐down cells, and became 69.7%/21.6%
in MOLM‐14 PRL‐3 KD cells (Fig 6A, b). Similarly, the ratio of
G1/S populations in MV4‐11 mock knock‐down cells shifted
from 51.4%/36.8% to 80.5%/14.6% in MV4‐11 PRL‐3 KD cells
(Fig 6B, b). Therefore, depletion of PRL‐3 retards cells entering
from G1 to S phase, implicating that PRL‐3 may have roles in
facilitating G1 to S phase transition to promote cell growth in
both MOLM‐14 and MV4‐11 cell lines. However, depletion of
PRL‐3 did not affect on apoptosis as presented in cell cycle
analysis (Fig 6A, b and B, b). Results showed that there were no
observable increments of sub‐G1 cell population after PRL‐3
knock‐down. It was further conﬁrmed by apoptosis analysis with
annexin‐V and 7‐AAD staining (Supporting Information Fig S4).
FACS analysis showed that silencing of PRL‐3 by siRNA did not
show substantial increment of apoptotic population in both cell
lines. These results imply that the role of PRL‐3 is primarily in
promoting G1‐S transition in MOLM‐14 and MV4‐11 cytokine
independent cells.
PRL‐3 antibody shows anti‐tumour effect in mouse leukaemia
model
Our results thus far showed FLT3 and PRL‐3 could synergisti-
cally drive AML cell growth. Given that clinical trials with FLT3
inhibitors have shown primary or secondary drug resistance
(Wiernik, 2010) and the implication of PRL‐3 in AML drug
resistance (Zhou et al, 2011), we herein attempted to develop an
alternative strategy by using PRL‐3 antibody to target PRL‐3 (an
intracellular phosphatase) expressing AML cells. We and others
have demonstrated the feasibility of antibody therapy against
intracellular oncoproteins for anticancer immunotherapy (Dao
Figure 6. PRL‐3 depletion inhibits the growth of FLT3‐ITD‐positive AML cells. The growth of PRL-3-depleted MOLM-14 and MV4-11 FLT3-ITD-positive AML
cells was analysed by MTS assay and flow cytometry.
A. (a) Knock-down of PRL-3 decreased cell number in FLT3-ITD positive MOLM-14 cells (mean  SD, n ¼ 3). (b) Depletion of PRL-3 accumulated cells in G1 phase
in MOLM-14 cells.
B. (a) Knock-down of PRL-3 decreased cell number in FLT3-ITD positive MV4-11 cells (mean  SD, n ¼ 3). (b) Depletion of PRL-3 accumulated cells in G1 phase in
MV4-11 cells. Representative data (right panel) from three independent experiments are shown.
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et al, 2013; Guo et al, 2011, 2012). To ascertain if the in vitro role
of PRL‐3 correlated with FLT3‐ITD‐driven AML tumour burden
in vivo, we developed a leukaemiamouse model using the lateral
tail vein injection of AML cells. PRL‐3 monoclonal antibodies
(mAb; Li et al, 2005) were subsequently used to target TF1‐ITD
AML cells which have elevated PRL‐3 expression (Fig 1C,
lane 4). Balb/c nude mice injected with TF1‐ITD cells
were divided into three treatment groups: (i) IgG antibody
sham‐treatment (IgG‐treated, n ¼ 11); (ii) PRL‐3 mAb (PRL‐3
mAb‐treated, n ¼ 11); or (iii) FLT3 mAb (FLT3 mAb‐treated,
Figure 7. PRL‐3 mAb exerts anti‐tumour therapeutic effects in a mouse model of AML.
A. (a, b) Results of immunotherapy on liver and spleen sizes in amouse model of AML. (a) Representative images of livers and spleens harvested from normal nude
mice (upper left panel) or nudemice 12–14 days after i.v. injection of TF1-ITD cells together with bi-weekly i.v. administration of control IgG (upper right panel),
PRL-3 mAb (lower left panel) or FLT3 mAb (lower right panel). (b) Quantitation of liver and spleen weights of mice as described in (a). Statistical differences
between data groups were determined using Student’s t-test from three independent experiments. p < 0.001; p ¼ 0.00121.
B. (a, b) Results of immunotherapy and PRL-3 knock-down on leukaemic infiltration in mouse bone marrow (BM) cells in a mouse model of AML. (a) BM cells from
nude mice 12–14 days after i.v. injection of (I) TF1, TF1-ITD cells together with bi-weekly i.v. administration of (II) control IgG or (III) PRL-3 mAb (lower left
panel) or (IV) TF1-ITD cells depleted of endogenous PRL-3 were analysed using flow cytometry analysis using the human-specific marker CD45þ to distinguish
TF1 human-derived AML cells. Percentages indicate proportion of CD45þ cells in the BM population analysed. (b) Quantitation of CD45þ engrafted cells as
described in (a). Statistical differences between two groups were determined using Student’s t-test (mean  SD, n ¼ 5, p < 0.001).
C. Kaplan–Meier survival analysis of PRL-3 mAb-treated (n ¼ 7) or control IgG-treated (n ¼ 7) mice in the TF1-ITD leukaemia mouse model (p < 0.001).
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n ¼ 11). After bi‐weekly administrations of IgG, PRL‐3 or FLT3
mAbs over 12–14 days, PRL‐3 mAb‐treated mice showed a
signiﬁcant reduction of liver and spleen sizes (Fig 7A, a),
indicative of reduced tumour burden. Liver and spleen weights
were decreased to 72.8 and 59.3% of untreated (IgG control)
group, respectively (p  0.001; Fig 7A, b). Notably, PRL‐3 mAb
treatment produced similar results to FLT3 mAb treatment
(Fig 7A, a and b). Previously, FLT3 mAb treatment was
demonstrated to have efﬁcacy in an FLT3 leukaemia mouse
model (Li et al, 2004). The current results corroborate a role of
PRL‐3 in FLT3‐ITD‐driven AML progression and indicate a novel
use of PRL‐3 antibody therapy to treat PRL‐3 positive AML
patients, in addition to other PRL‐3‐positive cancer types
previously investigated (Guo et al, 2012).
To understand the effect of PRL‐3 mAb in reducing leukaemia
burden, we assessed the engraftment of these human leukaemic
cells in mouse bone marrow. Twenty balb/c nude mice were
divided into four groups (Fig 7B, I–IV, n ¼ 5/group): Mice
injected with (I) TF‐1 cells; (II) TF1‐ITD cells þ IgG (IgG‐
treated); (III) TF1‐ITD þ PRL‐3 mAb (PRL‐3 mAb‐treated); (IV)
TF1‐ITD PRL‐3 KD (no treated). An antibody against the CD45
human speciﬁc haematopoietic cell surface marker (hCD45) was
used to distinguish and identify engrafted human leukaemic
cells from mouse host bone marrow cells by FACS analysis.
Group I mice showed 0.3% of CD45‐positive (hCD45þ) cells
engrafted in their bone marrows (Fig 7B, a, panel I). In contrast,
group II mice showed 9% of cells in their bone marrows were
hCD45þ (Fig 7B, a, panel II). Group III mice showed only 3.5%
of cells being hCD45þ (Fig 7B, a, panel III), indicating that PRL‐3
mAb treatment could reduce TF1‐ITD cell inﬁltration. Group IV
mice showed the effects of PRL‐3 silencing on leukaemia
development. We could detect only 0.7% of such hCD45þ cell
in mouse bone marrow from group IV mice (Fig 7B, a, panel IV),
suggesting that knock‐down of PRL‐3 was more effective than
PRL‐3 mAb treatment with regards to cancer cells engraftment in
mouse bone marrow. The statistical signiﬁcance of leukaemic
inﬁltration in the different groups of mice is summarized in Fig 7B
(b) (p < 0.001). Importantly, PRL‐3 mAb therapy prolonged the
survival rates for nudemice injectedwith TF1‐ITD cells.Micewith
a median survival of 19 days for PRL‐3 mAb‐treated but 16 days
for control IgG‐treated mice (Fig 7C; p < 0.001). Collectively, our
results here demonstrate a signiﬁcant beneﬁt of PRL‐3 immuno-
therapy in reducing FLT3‐ITD AML cell engraftment in bone
marrow and tumour burden, as well as in prolonging survival.
PRL‐3 expression in AML patients signiﬁcantly associates with
a shorter survival
To evaluate the clinical relevance and importance of PRL‐3
expression in AML, the correlation between PRL‐3 gene
expression and the overall survival in AML patients was
analysed using Cohort 1 (n ¼ 221) and a publicly available
dataset GSE12417 (n ¼ 163) (Metzeler et al, 2008). By univariate
Cox‐regression analysis, high levels of PRL‐3 expression were
associated with a shorter survival in both Cohort 1 (HR ¼ 1.327,
95% CI ¼ 1.057–1.664, p ¼ 0.015) and GSE12417 cohort
(HR ¼ 1.81, 95% CI ¼ 1.20–2.74, p ¼ 0.005). We noted that
the prognostic value of PRL‐3 was greater in AML patients with
normal karyotype (n ¼ 101) (HR ¼ 1.576, 95% CI ¼ 1.151–
2.156, p ¼ 0.005) than in AML patients with cytogenetic
complications (n ¼ 120) (HR ¼ 1.298, 95% CI ¼ 0.927–1.818,
p ¼ 0.129) in Cohort 1. We therefore focused on the relationship
between PRL‐3 and survival in such patients with normal
karyotype by Kaplan–Meier survival analysis using the following
three cohorts: (i) Cohort 1 (n ¼ 101), (ii) GSE 6891 (n ¼ 227)
and (iii) GSE12417 (n ¼ 163). In Cohort 1, high levels of PRL‐3
expression were signiﬁcantly associated with a shorter survival
(mean survival time ¼ 26 months, 95% CI ¼ 13–40 months)
compared to patients with low PRL‐3 expression levels (mean
survival time ¼ 60 months, 95% CI ¼ 39–81 months) in
patients with normal karyotype (log‐rank test, n ¼ 101,
p ¼ 0.028; Fig 8A). In concordance, Kaplan–Meier survival
analysis of AML patients with normal karyotype in the other two
independent cohorts, GSE 6891 and GSE12417, also revealed
that a high level of PRL‐3 mRNA expression was signiﬁcantly
associated with a shorter survival time (log‐rank test; p < 0.001
and p ¼ 0.025, respectively; Fig 8B and C). Together, these
results suggest that PRL‐3 expression is associated with poorer
overall survival in AML patients with a normal karyotype.
Multivariable Cox‐regression analysis reveals PRL‐3 as an
independent prognostic marker
To evaluate whether PRL‐3 is an independent prognostic marker
for survival in AML patients, multivariable Cox‐regression was
performed in Cohort 1 (n ¼ 221) with parameters including sex,
age, cytogenetic risk group, karyotype, FAB group, FLT3
mutation status, NPM mutation status and PRL‐3 mRNA
expression (Table 1). Importantly, high PRL‐3 mRNA expression
(p ¼ 0.001, HR ¼ 1.577, 95% CI ¼ 1.199–2.073) was
identiﬁed as an independent predictor for patient survival, in
addition to age (p < 0.001), cytogenetic risk group (intermedi-
ate, p ¼ 0.001; adverse, p < 0.001) and FLT3‐ITD mutation
(p ¼ 0.001). Consistently, examination of the GSE6891 dataset
(n ¼ 521; Verhaak et al, 2009) using multivariable analysis
likewise demonstrated that high PRL‐3 expression or FLT3‐ITD
mutation were independent predictors for patient survival. In
that dataset, we found that only a high level of PRL‐3 expression
(HR ¼ 1.488, 95% CI ¼ 1.194–1.855, p ¼ 0.0004) or FLT3‐ITD
mutation (HR ¼ 1.389, 95%CI ¼ 1.094–1.764, p ¼ 0.007) were
shown to be independent predictors for patients survival. These
consistent results from distinct datasets collectively indicate that
a high level expression of PRL‐3 is associated with poor survival,
and highlight PRL‐3 expression levels as an important and novel
prognostic marker independent of other known clinically
relevant prognostic markers for AML patients.
DISCUSSION
In this study, we presented three major ﬁndings: (i) the
molecular mechanism of PRL‐3 overexpression in promoting
AML cell growth in vitro, (ii) novel approach of using PRL‐3
antibody as unconventional therapies to target PRL‐3 expressing
AML cells for reducing tumour burden in animal model and
(iii) a clinical relationship between high PRL‐3 expression and
Research Article www.embomolmed.org
Oncogenic roles of PRL‐3 in AML
1360  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2013) 5, 1351–1366
poorer survival in AML patients. Collectively, our ﬁndings
suggest that PRL‐3 could be a putative novel therapeutic target
and a prognostic marker to predict poorer survival for AML
patients with FLT3‐ITD mutations.
FLT3 and its mutants have received much attention as
therapeutic drug targets, due to their prominent roles in cell
proliferation and differentiation of myeloblasts (Levis &
Small, 2003). So far, several FLT3 selective inhibitors have
been developed and examined in AML patients as single agents
or in combination with chemotherapy (Wiernik, 2010). How-
ever, recent clinical trials with FLT3 inhibitors showed primary
or secondary drug resistance and differential clinical outcomes
(Weisberg et al, 2009). Thus, the discovery of critical
downstream target genes of FLT3 mutation will be important
for improved therapies. Herein, the demonstration of PRL‐3 as a
putative novel target for AML therapy is a timely and an
important endeavour. Currently, only a handful of studies have
addressed a possible link between PRL‐3 expression and
leukaemia (Fagerli et al, 2008; Zhou et al, 2011). Here we
report that AML cells and patient samples with FLT3‐ITD
mutations have a high incidence of PRL‐3 overexpression, an
observation supported by the analysis of four separate AML
patient cohorts in a total of 1158 patients. PRL‐3 is shown
to be a downstream target of FLT3‐ITD mutation, with a FLT3‐
Src‐STAT5 pathway regulating PRL‐3 mRNA expression.
Importantly, PRL‐3 upregulation by FLT3‐ITD mutations
associated with cancer progression, a phenomenon potentially
explained by the PRL‐3‐induced activation of oncogenic
transcription factor c‐Jun/AP‐1. c‐Jun is over‐expressed in
AML patients and contributes to a block in granulocyte
differentiation and development of AML (Pulikkan et al, 2010;
Rangatia et al, 2003), thus implicating an important role of AP‐1
activation by PRL‐3 in tumour development. In addition,
treatment with MEK/JNK inhibitors (U0126, SP600125) or
AP‐1 inhibitor (curcumin) resulted in a decrease in PRL‐3 driven‐
cell growth, suggesting that PRL‐3 function is dependent on
MEK/ERK and/or JNK signalling. Several reports have shown
that PRL‐3 could activate ERK through regulation of Rho family
GTPase (Fiordalisi et al, 2006; Ming et al, 2009) or integrin b
(Peng et al, 2009) in various solid cancer cells, but the detailed
molecular mechanisms are not fully answered yet. In addition, it
has been recently reported that PRLs (PRL‐1, PRL‐2 and PRL‐3)
can promote AP‐1 activity and increase cell proliferation in non‐
small cell lung cancer cells (Hwang et al, 2011). Consistently,
we demonstrate that PRL‐3 played oncogenic roles in AML cell
growth by promoting G1 to S phase transition in cell cycle as well
as anti‐apoptosis.
More importantly, we showed PRL‐3 upregulation could
contribute to AML progression, particularly in patients with
normal karyotype, suggesting that PRL‐3was a viable therapeutic
target for this group of patients, whose clinical outcomes to
conventional therapies are highly heterogeneous (Baldus &
Bullinger, 2008; Gaidzik & Dohner, 2008; Small, 2006). Moreover
multivariable analysis validated PRL‐3 expression as an indepen-
dent prognostic marker in two distinct datasets (Cohort 1,
GSE6891; Table 1). These results suggest that PRL‐3 is a useful
prognostic marker and a therapeutic target in AML patients.
Lastly, we demonstrated an unconventional antibody therapy
approach to target intracellular PRL‐3 oncoprotein for anti‐AML
therapy in mice (Fig 7). Antibodies are traditionally used to
target extracellular (surface) proteins and have never been used
to target intracellular proteins because antibodies are generally
believed to be too large (150 kDa) to enter cells, leaving a large
Figure 8. Elevated expression of PRL‐3 correlates with a shorter survival
in three independent AML patient cohorts.
A–C. Kaplan–Meier analysis of overall survival (OS) in normal karyotype AML
patients for PRL-3 mRNA expression in (A) Cohort 1 AML patients,
n ¼ 101, (B) GSE6891, n ¼ 227 and (C) GSE12417, n ¼ 163. Statisti-
cally significant p values (using the log-rank test) are indicated in the
figures.
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intracellular treasure of potential cancer‐speciﬁc therapeutic
targets untapped in terms of antibody therapy or vaccination.
The possible mechanisms for how antibodies could target
intracellular oncoproteins for anti‐cancer were proposed in
recent review articles (Ferrone, 2011; Guo et al, 2008, 2011;
Hong & Zeng, 2012). Herein, this untraditional approach was
further evaluated by performing PRL‐3 mAb therapy in mice
carrying tumours formed by TF1‐ITD cells expressed both FLT3‐
ITD and PRL‐3 proteins. Compared to control IgG‐treated mice,
mice treated with FLT3 mAb (targeting extracellular FLT3
receptor), or treated with PRL‐3 mAb (targeting intracellular
PRL‐3) showed reduction in the sizes of spleen and liver, two
enlarged organs commonly used for indicator of leukaemia
burden. This result suggests a potential value of PRL‐3 antibody
therapy for AML patients associated with PRL‐3 overexpression.
Since FLT3 inhibition both alone and in combination with
standard chemotherapy have proven clinical limitations, PRL‐3
antibody therapymight provide a viable alternative treatment for
AML patients with the FLT3‐ITDmutation associated with PRL‐3
overexpression. Such an antibody treatment might be particu-
larly useful and speciﬁc to AML patients as leukaemia cells are
easily accessible and are in direct contact with antibodies in their
circulating system. The prospect of new therapeutic avenues by
targeting PRL‐3 in AML patients should be further explored.
MATERIALS AND METHODS
Cell lines and primary patient samples
TF‐1 and MV4‐11 cells were purchased from ATCC (American type
culture collection, Manassas, VA). MOLM‐14 cell line was obtained
in house. TF‐1 cells were cultured in RPMI 1640 (Invitrogen, Carlsbad,
CA) supplemented with heat‐inactivated 10% foetal bovine serum
(Hyclone Laboratories, Inc., Logan, UT) and supplemented with 2 ng/ml
human IL‐3 (R & D system, Inc., Minneapolis, MN). TF1‐ITD and
TF1‐PRL‐3 cells were prepared as described previously (Kim et al, 2005;
Zhou et al, 2011). Bone marrow (BM) blast cells were obtained from
newly diagnosed AML patients with written informed consent from
National University Hospital, Singapore. This study was approved by
Institutional Review Board (IRB) of National University of Singapore.
Table 1. Multivariate Cox‐regression analysis reveal PRL‐3 as an independent prognostic marker
Clinicopathological variables
Cox‐regression analysis of AML patient survival
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) p‐Value Hazard ratio (95% CI) p‐Value
Age (n ¼ 221) 1.034 (1.022–1.046) <0.0001 1.032 (1.019–1.045) <0.0001
Sex
Female (n ¼ 112) 1 Reference
Male (n ¼ 109) 0.951 (0.681–1.326) 0.765
Cytogenetic risk group
Favourable (n ¼ 63) 1 Reference 1 Reference
Intermediate (n ¼ 142) 3.131 (1.950–5.026) <0.0001 2.488 (1.458–4.244) 0.001
Adverse (n ¼ 16) 5.528 (2.817–10.847) <0.0001 4.431 (2.067–9.499) <0.0001
Karyotype
Normal (n ¼ 101) 1 Reference
Others (n ¼ 120) 0.651 (0.465–0.911) 0.012
FLT3 mutation status
Normal (n ¼ 141) 1 Reference 1 Reference
TKD (n ¼ 29) 0.644 (0.358–1.156) 0.141 0.665 (0.355–1.243) 0.201
ITD (n ¼ 50) 1.920 (1.322–2.789) 0.001 1.697 (1.303–2.896) 0.001
ITD/TKD (n ¼ 1) 1.963 (0.272–14.155) 0.504 1.004 (0.133–7.590) 0.997
NPM mutation status
Normal (n ¼ 163) 1 Reference
Mutant (n ¼ 58) 1.319 (0.917–1.897) 0.136
PRL-3 mRNA expression 1.306 (1.041–1.639) 0.021 1.577 (1.199–2.073) 0.001
FAB group (missing; n ¼ 10)
FAB group 1 (n ¼ 50) 1 Reference
FAB group 2 (n ¼ 64) 0.736 (0.457–1.184) 0.206
FAB group 3 (n ¼ 12) 0.592 (0.231–1.519) 0.276
FAB group 4 (n ¼ 44) 0.662 (0.392–1.116) 0.122
FAB group 5 (n ¼ 35) 1.073 (0.640–1.799) 0.789
FAB group 6 (n ¼ 4) 1.504 (0.461–4.906) 0.499
FAB group 7 (n ¼ 2) 6.913 (1.598–29.903) 0.010
PRL-3 acts as a novel prognostic marker in AML. By multivariate Cox-regression analysis using backward conditional stepwise method with a removal limit of
p > 0.05, PRL-3 constituted one of the key independent predictors for poorer patient survival in our Cohort 1 (n ¼ 221).
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Chemicals and reagents
FLT3 inhibitor (PKC412), MEK inhibitor (U0126), p38 MAPK inhibitor
(SB203580) and JNK inhibitor (SP600125) were purchased from LC
Laboratories (Woburn, MA). FLT3 inhibitor (CEP‐701) and Src kinase
inhibitors (SU6656 and PP2) were purchased from Sigma (St. Louis, MO).
Antibodies to FLT3, STAT5, JAK2, Src, ERK, c‐Jun, pFLT3, pJAK2, pSTAT5,
pSrc and p‐c‐Jun were purchased from Cell Signalling Technologies
(Beverly, MA). GAPDH antibody was obtained from Millipore (Billerica,
MA). Anti‐CD45‐APC and LightShift chemiluminescent EMSA kit were
from Pierce Biotechnology, Inc. (Rockford, IL). Mouse anti‐PRL3 antibody
was from hybridoma clone 318 as reported previously (Li et al, 2005).
SEAP reporter assay kit was purchased from Clontech (Palo Alto, CA) and
Phospha‐Light™ from Applied Biosystems (Bedford, MA).
Detection of FLT3‐ITD mutation and expression of PRL‐3 by
RT‐PCR
Total RNA was extracted from AML patients’ bone marrow cells using
RNeasy minikit (Qiagen, Chatsworth, CA) according to the manufac-
turer’s instructions. cDNA was synthesized from total RNA by reverse
transcriptase III (Invitrogen) and ampliﬁed by PCR as described before
(Quentmeier et al, 2003). The primer sets for RT‐PCRwere summarized;
FLT3‐ITD, 50‐GCAATTTAGGTATGAAAGCCAGC‐30 and 50‐CTTTCAGCATTTT
GACGGCAACC‐30 , PRL‐3, 50‐GGGACTTCTCAGGTCGTGTC‐30 and 50‐
AGCCCCGTACTTCTTCAGGT‐30 , and the b‐actin gene was 5’‐
GTGGGGCGCCCCAGGCACCA‐3’ and 5’‐CTCCTTAATGTCACGCACGATTTC‐
3’. The PCR products were analysed on a 5% polyacrylamide gel, stained
with ethidium bromide, and then visualized with GelDoc imager
(BioRad, Inc., Hercules, CA).
Quantitative real time PCR
Quantitative real time PCR (Q‐RT‐PCR) was used to measure the mRNA
expression levels of PRL‐3 at human BM samples and AML cell lines (ABI
7500 Fast Real Time PCR system). The cDNAs were served as template
for Q‐RT‐PCR by using TaqMan® Universal PCR Master Mix kit (Applied
Biosystems, Foster City, CA). Each 10 ml of quantitative PCR reaction
mixture contained 5 ml of 2 TaqMan® Universal Master Mixture
(Applied Biosystems), 4.5 ml of diluted cDNAmixture and 0.5 ml of gene
speciﬁc probe. To standardize the quantiﬁcation of the selected target
genes, GAPDH served as internal controls and were quantiﬁed on the
same plate as the target genes.
Western blot analysis
Cells were lysed using modiﬁed RIPA buffer (50 mM Tris–HCl, 150 mM
NaCl, 1% NP‐40, pH 8.0, 1 protease inhibitor cocktail) and lysates
were subjected to Western blotting with indicated primary antibodies.
Proteins recognized by the antibodies were detected using the
chemiluminescent detection kit (Pierce, Thermo Scientiﬁc, Rockford, IL).
Transient transfection of siRNA or reporter vector
TF‐1, TF1‐ITD, MOLM‐14 or MV4‐11 cells were re‐suspended at
2  106 cells per 100 ml of appropriate Nucleofector kit solution
(Amaxa Biosystems, Cologne, Germany) and were nucleofected with
2 mg of FLT3 SMARTpool siRNA duplexes (Dharmacon Research,
Milipore), PRL‐3 siRNA, Signal Silence STAT5 siRNA I/II (Cell Signalling
Technologies), AP‐1 SEAP reporter vector, ERK siRNA, JNK siRNA or non‐
silencing siRNA (Santa Cruz Biotechnology, CA). After nucleofection, the
cells were immediately mixed with 500 ml of pre‐warmed culture
medium and transferred to culture plates for incubation. Samples were
collected for protein extraction as described above.
Electrophoretic mobility shift assay (EMSA)
The Transcription Factor Database (TRANSFAC) (Wingender et al, 1996)
was used to predict possible transcription factor binding sites on
human PRL‐3 promoter region. Nuclear extracts were prepared using
NE‐PER nuclear protein extraction kit (Pierce, Thermo Scientiﬁc). For
EMSA probes, 30 bp long, complementary sense and antisense strands
of DNA oligonucleotides were annealed and diluted to 50 fmol/ml. DNA
probes (50 fmol/ml) and nuclear extracts were mixed with EMSA buffer
[50 mM MgCl2, 1% glycerol, 0.01% NP‐40, 1 mM DTT and 0.1 mg/ml
poly (dI‐dC)] and incubated at room temperature for 30 min. In the
competition reaction, unlabelled competitor was added in at least 10:1
molar excess over the biotinylated probe. Reaction mixtures were run
on a native gel and visualised by LightShift chemiluminescent EMSA
detection kit. The probe sequences (sense strand) used in this study
include; S1, 50‐GGTGATGTTTTCTGGAAGTGTGGGT‐30 , S2, 50‐CCA-
TAAGTTCTTGGAAGCTGCGGCTT‐30 and STAT5 competitor sequence,
50‐AGATTTCTAGGAATTCAATCC‐30 .
Luciferase reporter assay
A5.4 kb upstream region of PRL‐3 (5556 to5331, S1a, numbered
from a transcription initiation site) and its 50‐sequential deletion
fragments (5472 to5331,5440 to5331 and5399 to5331;
S1b, S1c and S1d, respectively) were subcloned into the pGL‐Luc‐basic
vector. STAT5A and STAT5B expression vectors were purchased from
OriGene Technologies, Inc. (Rockville, MD). TF‐1 cells were seeded in 6‐
well plate and transfected with an expression vector of STAT5A or
STAT5B along with 1.5 mg of an appropriate luciferase reporter
construct by nucleofection method (Lonza Cologne AG, Switzerland).
Luciferase assays were performed using Dual‐Luciferase Reporter
system (Promega, Madison, WI), in which relative ﬁreﬂy luciferase
activities were calculated by normalizing transfection efﬁciency
according to the renilla luciferase activities. The expression level of
STAT5A or STAT5B was determined by Western blotting analysis.
Secreted alkaline phosphatase (SEAP) assay
The AP‐1 reporter vector (AP1‐SEAP) was purchased from Clontech.
TF1‐GFP cells and TF1‐PRL‐3 cells were transfected with 200 ng of
AP1‐SEAP vector and incubated for 24 h. The culture supernatant was
collected, heated at 65°C for 30 min, and assayed for alkaline
phosphatase activity as follows; 30 ml of supernatant was incubated
with 120 ml of assay buffer for 5 min, at which time 1:20 diluted CSPD
substrate was added, and samples were read on a TECAN microplate
reader (Maennedorf, Switzerland).
Cell viability assay
AML cells (1  104) were seeded into each well of 96‐well tissue
culture plates in 100 ml growth media and viable cells were
measured after seeding with different inhibitors for 72 h using the
CellTiter96Aqueous cell proliferation assay kit (Promega). Brieﬂy, an
aliquot of 20 ml MTS mixture was added at the indicated time of assay
and reactions were performed at 37°C for 2 h. And absorbance was read
at 490 nm wavelength using TECAN microplate reader. After establish-
ment of linear relationship between cell numbers and absorbance from
each cell line, acquired absorbance converted to cell number.
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Cell cycle analysis
The DNA content of cultured cells was quantitated by staining with
propidium iodide (PI) and analysed by ﬂow cytometry (BDLSR11, Becton
Dickinson, San Jose, CA). Brieﬂy, cells were harvested with PBS and ﬁxed
with cold 70%ethanol at 4°C for 30 min.The cells werewashedwith PBS
and then resuspended in 500 ml of PI staining solution and incubated for
30 min at room temperature. Sampleswere then examined and analysed
for cell cycle phase (Modﬁt LT2.0, Becton Dickinson).
Annexin‐V and 7‐aminoactinomycin D (7‐AAD) staining
TF1‐GFP and TF1‐PRL‐3 cells were harvested with PBS after 48 h culture
in the lack of cytokine supplement. The cells were washed with PBS twice
and incubated with annexin‐V and 7‐AAD staining solution for 30 min at
room temperature. After staining, cells were subjected to FACS analysis.
Cell line generation
To generate PRL‐3 knock‐down cell lines, pRS‐PRL‐3‐shRNA (OriGene
Technologies) was transfected into TF1‐ITD cells. The resulting PRL‐3‐
KD cell lines were selected with puromycin, and conﬁrmed by Western
blot analysis. TF1‐ITD PRL‐3‐KD cells were used for mice injection.
Anti‐Leukaemic effects in mouse model
All animal studies as described previously (Guo et al, 2008) have been
approved by Institutional Animal Care and Use Committee (IACUC).We
followed the policies from the Animal Facility Center of The Agency for
Science, Technology and Research (ASTAR), Singapore. Balb/c nude
mice were obtained from Biological Resource Center (ASTAR,
Singapore). Nude mice were intravenously injected with 1  106
TF1‐ITD cells. Three days later, mice were randomly divided into three
treatment groups: injected twice weekly with IgG (sham treated,
n ¼ 11), PRL‐3 mAb (PRL‐3 treated, n ¼ 11) and FLT3 mAb (FLT3
treated, n ¼ 11). For survival study, mice treated with IgG (n ¼ 7) or ‐
treated with PRL‐3 mAb (n ¼ 7) were used and observed daily. Mice
injected with TF‐1 cells were used as controls for mice injected with
TF1‐ITD cells. Organs were isolated and inspected for macroscopic
metastases at the end of the experiments (Guo et al, 2008).
Human leukaemic cells engraftment analysis
Nude mice were intravenously injected with 1  106 TF‐1, TF1‐ITD or
TF1‐ITD PRL‐3 KD cells. Mice injected with TF1‐ITD cells were divided
into two groups and bi‐weekly treated with control IgG or PRL‐3 mAb.
At the end of experiments, bone marrow cells were isolated and stained
with human speciﬁc haematopoietic cell surface marker, CD45‐APC
antibody (Pierce, Thermo Scientiﬁc), and analysed by ﬂow cytometry.
Analysis of AML cancer patient microarray data
Details of all human AML patients datasets used in this study are
summarized below and shown in Table 2. A total of ﬁve independent
AML patient datasets were analyzed: (i) Our unpublished dataset
(Cohort 1), analysed on Affymetrix U133Plus2 arrays from Belfast, UK;
(ii) GEO‐accessible GSE1159 dataset (Valk et al, 2004); (iii) GEO‐
accessible GSE6891 dataset (Verhaak et al, 2009); (iv) GEO‐accessible
GSE15434 dataset (Kohlmann et al, 2010) and (v) GEO‐accessible
GSE12417 dataset (Metzeler et al, 2008). Our summary showed the
available information in each dataset. Datasets were pre‐processed
using R and Bioconductor for normalization. The median value was
used as a cut‐off point to differentiate high and low levels of PRL‐3
(average of two PRL‐3 probes; 206574 and 209695). Statistical
analyses were performed using SPSS19.0 (IBM, Singapore). Correlation
between PRL‐3 expression and FLT3‐ITD mutation status was analysed
by Fisher exact test or Chi‐square test where applicable.The association
between PRL‐3 expression and survival time was analysed by Kaplan–
Meier analysis compared by log‐rank test. p < 0.05 was considered
signiﬁcant. Cox‐regression analysis with backward conditional step-
wise selection with a removal limit of p > 0.05 was performed to
identify independent predictors for AML patient survival.
The paper explained
PROBLEM:
The FLT3-ITDmutations are detected in 25–30% of AML patients
and are associated with poor prognosis. Targeting FLT3-ITD
mutations are a promising therapeutic approach for AML,
however, clinical trials with FLT3 inhibitors have showed limited
success. Insights into how FLT3mutation leads to the diseasewill
offer novel therapeutic opportunities.
RESULTS:
This study investigated the regulation and function of PRL-3, a
metastasis-associated phosphatase, in leukaemia cell lines and
AML patient samples associated with FLT3-ITD mutations. PRL-3
overexpression is mediated by the FLT3-Src-STAT5 signalling
pathway in leukaemia cells, results in an activation of the AP-1
transcription factors via the ERK and JNK pathway. Depletion of
PRL-3 attenuates cell growth and cell cycle progression in vitro
whereas overexpression of PRL-3 enhances leukaemia devel-
opment in vivo. PRL-3 antibody therapy reduced tumour burden
in a leukaemia mouse model. The FLT3-ITD mutation was
clinically associated with an increase in PRL-3 expression in four
independent cohorts in a total of 1158 AML patients. Higher PRL-
3 expression was significantly (p  0.001) associated with
shorter survival in AML patients.
IMPACT:
The mechanistic findings on the FLT3-ITD-STAT5 signalling-
mediated PRL-3 regulation unveiled the underlyingmechanism of
elevated PRL-3 expression that results in cell growth and tumour
burden. Targeting PRL-3 reversed the oncogenic effects in FLT3-
ITD AML models in vitro and in vivo, suggesting that PRL-3 is a
promising therapeutic target. Performing multivariable Cox-
regression in 221 AML patients of Cohort 1 identified PRL-3 as a
novel prognosticmarker independent of other clinical parameters.
Research Article www.embomolmed.org
Oncogenic roles of PRL‐3 in AML
1364  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2013) 5, 1351–1366
Author contributions
JEP designed and performed experiments, analysed data and
wrote the paper; JBZ created the stable cell lines and contributed
to discussion; HFY, AQOA‐A revised the manuscript, analysed
and interpreted the dataset; KG performed all mice experiments;
WJC provided patient samples and AML cell lines; SZ analysed
dataset; PJV provided and analysed dataset; CWH, discussed
and edited the manuscript; KM provided and analysed dataset;
QZ designed, supervised and revised the manuscript. All co‐
authors contributed to the revision of the manuscript.
Acknowledgements
We thank Bobby Cheng Peow Tan and Samantha Quah Yiling for
technical assistance and Dr. Alice Tay Wan Ngee for her critical
reading of the manuscript. We are grateful to Drs. Eng Chon
Boon and Rajeev Singh from NUH‐NUS Tissue Repository for
their great help in providing human cancer samples in this study.
This work was supported by research grant from the Agency of
Science, Technology and Research (AStar, Singapore). Profes-
sor Ken Mills was supported by the Northern Ireland Leukemia
Research Fund (NILRF).
Supporting Information is available at EMBO Molecular
Medicine online.
The authors declare that they have no conﬂict of interest.
References
Al-Aidaroos AQ, Zeng Q (2010) PRL-3 phosphatase and cancer metastasis. J
Cell Biochem 111: 1087-1098
Balasubramanian S, Eckert RL (2007) Curcumin suppresses AP1 transcription
factor-dependent differentiation and activates apoptosis in human
epidermal keratinocytes. J Biol Chem 282: 6707-6715
Baldus CD, Bullinger L (2008) Gene expression with prognostic implications
in cytogenetically normal acute myeloid leukemia. Semin Oncol 35: 356-
364
Bessette DC, Qiu D, Pallen CJ (2008) PRL PTPs: mediators and markers of
cancer progression. Cancer Metastasis Rev 27: 231-252
Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, Courtneidge SA (2000)
SU6656, a selective Src family kinase inhibitor, used to probe growth factor
signaling. Mol Cell Biol 20: 9018-9027
Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J,
Maslak P, Casey E, et al (2013) Targeting the intracellular WT1
oncogene product with a therapeutic human antibody. Sci Transl Med 5:
176ra133
Eferl R, Wagner EF (2003) AP-1: a double-edged sword in tumorigenesis. Nat
Rev Cancer 3: 859-868
Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B,
Waage A, Aarset H, Dai HY, et al (2008) Overexpression and involvement in
migration by the metastasis-associated phosphatase PRL-3 in human
myeloma cells. Blood 111: 806-815
Ferrone S (2011) Hidden immunotherapy targets challenge dogma. Sci Transl
Med 3: 99ps38
Fiordalisi JJ, Keller PJ, Cox AD (2006) PRL tyrosine phosphatases regulate
rho family GTPases to promote invasion and motility. Cancer Res 66:
3153-3161
Gaidzik V, Dohner K (2008) Prognostic implications of gene mutations in
acute myeloid leukemia with normal cytogenetics. Semin Oncol 35: 346-
355
Guo K, Li J, Tang JP, Tan CP, Hong CW, Al-Aidaroos AQ, Varghese L, Huang C,
Zeng Q (2011) Targeting intracellular oncoproteins with antibody therapy
or vaccination. Sci Transl Med 3: 99ra85
Guo K, Li J, Wang H, Osato M, Tang JP, Quah SY, Gan BQ, Zeng Q (2006) PRL-3
initiates tumor angiogenesis by recruiting endothelial cells in vitro and in
vivo. Cancer Res 66: 9625-9635
Guo K, Tang JP, Jie L, Al-Aidaroos AQ, Hong CW, Tan CP, Park JE, Varghese L,
Feng Z, Zhou J, et al (2012) Engineering the first chimeric antibody in
targeting intracellular PRL-3 oncoprotein for cancer therapy in mice.
Oncotarget 3: 158-171
Guo K, Tang JP, Tan CP, Wang H, Zeng Q (2008) Monoclonal antibodies target
intracellular PRL phosphatases to inhibit cancer metastases inmice. Cancer
Biol Ther 7: 750-757
Hebestreit K, Gro¨ttrup S, Emden D, Veerkamp J, Ruckert C, Klein H.-U, Mu¨ller-
Tidow C, Dugas M (2012) Leukemia Gene atlas – a public platform for
integrative exploration of genome-wide molecular data. PLoS One 7:
e39148
Hong CW, Zeng Q (2012) Awaiting a new era of cancer immunotherapy.
Cancer Res 72: 3715-3719
Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V,
Scheuch H, Beug H, Wagner EF (2007) p38[alpha] suppresses normal and
cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet
39: 741-749
Table 2. Details of all human AML patients datasets used in this study
No.
AML
patient
dataset
Total no. of
AML patients
with clinical
dataset
No. of AML
patients with
normal
karyotype
Information available
Reference
Figures or tables in
this report using
dataset information
PRL‐3
expression
level
FLT3‐ITD
mutation
status
Survival
data
1 Cohort 1 221 101 Y Y Y In-houseb Figs 1 and 8, Table 1
2 GSE1159 285 NAa Y Y N Valk et al (2004) Fig 1
3 GSE6891 521 227 Y Y Y Verhaak et al (2009) Figs 1 and 8
4 GSE15434 251 251 Y Y N Kohlmann et al (2010) Fig 1
5 GSE12417 163 163 Y N Y Metzeler et al (2008) Fig 8
Patient data was extracted and analysed in the leukaemia Gene Atlas platform (Hebestreit et al, 2012).
aNo information available on cytogenetic profile of patients.
bCohort 1 is a compilation of an in-house dataset and a MILE dataset from Belfast/MILE cohort.
Research Articlewww.embomolmed.org
Jung Eun Park et al.
EMBO Mol Med (2013) 5, 1351–1366  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1365
Hwang JJ, Min SH, Sin KH, Heo YS, Kim KD, Yoo OJ, Lee SH (2011) Altered
expression of phosphatase of regenerating liver gene family in non-small
cell lung cancer. Oncol Rep 27: 535-540
Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M, Small D (2005) Pim-1 is up-
regulated by constitutively activated FLT3 and plays a role in FLT3-
mediated cell survival. Blood 105: 1759-1767
Kohlmann A, Bullinger L, Thiede C, Schaich M, Schnittger S, Dohner K, Dugas
M, Klein HU, Dohner H, Ehninger G, et al (2010) Gene expression profiling in
AML with normal karyotype can predict mutations for molecular markers
and allows novel insights into perturbed biological pathways. Leukemia 24:
1216-1220
Levis M, Small D (2003) FLT3: ITDoes matter in leukemia. Leukemia 17: 1738-
1752
Li J, Guo K, Koh VWC, Tang JP, Gan BQ, Shi H, Li HX, Zeng Q (2005) Generation
of PRL-3- and PRL-1-specific monoclonal antibodies as potential
diagnostic markers for cancer metastases. Clin Cancer Res 11: 2195-
2204
Li Y, Li H, Wang M-N, Lu D, Bassi R, Wu Y, Zhang H, Balderes P, Ludwig DL,
Pytowski B, et al (2004) Suppression of leukemia expressing wild-type or
ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing
antibody. Blood 104: 1137-1144
Liang F, Liang J, Wang WQ, Sun JP, Udho E, Zhang ZY (2007) PRL3 promotes
cell invasion and proliferation by down-regulation of Csk leading to Src
activation. J Biol Chem 282: 5413-5419
Lin KR, Lee SF, Hung CM, Li CL, Yang-Yen HF, Yen JJ (2007) Survival factor
withdrawal-induced apoptosis of TF-1 cells involves a TRB2-Mcl-1 axis-
dependent pathway. J Biol Chem 282: 21962-21972
Lowenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J
Med 341: 1051-1062
Matsukawa Y, Semba S, Kato H, Koma Y, Yanagihara K, Yokozaki H (2010)
Constitutive suppression of PRL-3 inhibits invasion and proliferation of
gastric cancer cell in vitro and in vivo. Pathobiology 77: 155-162
Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland
MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, et al (2008) An 86-
probe-set gene-expression signature predicts survival in cytogenetically
normal acute myeloid leukemia. Blood 112: 4193-4201
Ming J, Liu N, Gu Y, Qiu X, Wang EH (2009) PRL-3 facilitates angiogenesis and
metastasis by increasing ERK phosphorylation and up-regulating the levels
and activities of Rho-A/C in lung cancer. Pathology 41: 118-126
Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, Gruning W,
Kratz-Albers K, Serve S, Steur C, et al (2000) Flt3 mutations from patients
with acute myeloid leukemia induce transformation of 32D cells mediated
by the Ras and STAT5 pathways. Blood 96: 3907-3914
NakaoM, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto
T, Misawa S (1996) Internal tandem duplication of the flt3 gene found in
acute myeloid leukemia. Leukemia 10: 1911-1918
Nam J-S, Ino Y, Sakamoto M, Hirohashi S (2002) Src family kinase inhibitor
PP2 restores the E-cadherin/catenin cell adhesion system in human cancer
cells and reduces cancer metastasis. Clin Cancer Res 8: 2430-2436
Odgerel T, Kikuchi J, Wada T, Shimizu R, Futaki K, Kano Y, Furukawa Y (2007)
The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic
cells depending on the presence of FLT3 mutations. Oncogene 27: 3102-
3110
Peng L, Xing X, Li W, Qu L, Meng L, Lian S, Jiang B, Wu J, Shou C (2009) PRL-3
promotes the motility, invasion, and metastasis of LoVo colon cancer cells
through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling. Mol Cancer 8:
110
Pulikkan JA, Dengler V, Peer Zada AA, Kawasaki A, Geletu M, Pasalic Z,
Bohlander SK, Ryo A, Tenen DG, Behre G (2010) Elevated PIN1 expression by
C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation
through c-Jun in AML. Leukemia 24: 914-923
Quentmeier H, Reinhardt J, Zaborski M, Drexler HG (2003) FLT3 mutations in
acute myeloid leukemia cell lines. Leukemia 17: 120-124
Rangatia J, Vangala RK, Singh SM, Peer Zada AA, Elsasser A, Kohlmann A,
Haferlach T, Tenen DG, Hiddemann W, Behre G (2003) Elevated c-Jun
expression in acute myeloid leukemias inhibits C/EBPalpha DNA binding via
leucine zipper domain interaction. Oncogene 22: 4760-4764
Ren T, Jiang B, Xing X, Dong B, Peng L, Meng L, Xu H, Shou C (2009) Prognostic
significance of phosphatase of regenerating liver-3 expression in ovarian
cancer. Pathol Oncol Res 15: 555-560
Robinson LJ, Xue J, Corey SJ (2005) Src family tyrosine kinases are activated by
Flt3 and are involved in the proliferative effects of leukemia-associated Flt3
mutations. Exp Hematol 33: 469-479
Rockova V, Abbas S, Wouters BJ, Erpelinck CAJ, Beverloo HB, Delwel R, van
Putten WLJ, Lo¨wenberg B, Valk PJM (2011) Risk stratification of
intermediate-risk acute myeloid leukemia: integrative analysis of a
multitude of gene mutation and gene expression markers. Blood 118:
1069-1076
Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE,
Choti MA, Lengauer C, Kinzler KW, et al (2001) A phosphatase associated
with metastasis of colorectal cancer. Science 294: 1343-1346
Seidel HM, Milocco LH, Lamb P, Darnell JE, Stein RB, Rosen J (1995) Spacing of
palindromic half sites as a determinant of selective STAT (signal
transducers and activators of transcription) DNA binding and transcrip-
tional activity. Proc Natl Acad Sci 92: 3041-3045
Small D (2006) FLT3 mutations: biology and treatment. Hematology 2006:
178-184
Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses
T, Allebach J, Small D (2004) Single-agent CEP-701, a novel FLT3 inhibitor,
shows biologic and clinical activity in patients with relapsed or refractory
acute myeloid leukemia. Blood 103: 3669-3676
Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W (2003)
Overexpression and constitutive activation of FLT3 induces STAT5 activation
in primary acutemyeloid leukemia blast cells. Clin Cancer Res 9: 2140-2150
Sternberg DW, Licht JD (2005) Therapeutic intervention in leukemias that
express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and
challenges. Curr Opin Hematol 12: 7-13
Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van
Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ,
Lowenberg B, et al (2004) Prognostically useful gene-expression profiles in
acute myeloid leukemia. N Engl J Med 350: 1617-1628
Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S,
Lowenberg B, Delwel R, Valk PJ (2009) Prediction of molecular subtypes in
acute myeloid leukemia based on gene expression profiling. Haematologica
94: 131-134
Wang L, Shen Y, Song R, Sun Y, Xu J, XuQ (2009) An anticancer effect of curcumin
mediated by down-regulating phosphatase of regenerating liver-3 expression
on highly metastatic melanoma cells. Mol Pharmacol 76: 1238-1245
Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD (2009) FLT3 inhibition
and mechanisms of drug resistance in mutant FLT3-positive AML. Drug
Resist Updat 12: 81-89
Weisberg E, Sattler M, Ray A, Griffin JD (2010) Drug resistance inmutant FLT3-
positive AML. Oncogene 29: 5120-5134
Wiernik PH (2010) FLT3 inhibitors for the treatment of acute myeloid
leukemia. Clin Adv Hematol Oncol 8: 429-436, 444
Wingender E, Dietze P, Karas H, Knu¨ppel R (1996) TRANSFAC: a database on
transcription factors and their DNA binding sites. Nucleic Acids Res 24: 238-
241
Zeng Q, Hong W, Tan YH (1998) Mouse PRL-2 and PRL-3, two potentially
prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem
Biophys Res Commun 244: 421-427
Zhang W, Liu HT (2002) MAPK signal pathways in the regulation of cell
proliferation in mammalian cells. Cell Res 12: 9-18
Zhang Y, Pu X, Shi M, Chen L, Song Y, Qian L, Yuan G, Zhang H, Yu M, Hu M,
Shen B, Guo N (2007) Critical role of c-Jun overexpression in liver metastasis
of human breast cancer xenograft model. BMC Cancer 7: 145
Zhou J, Bi C, Chng W, Cheong L, Liu S, Mahara S, Tay K, Zeng Q, Li J, Guo K, et al
(2011) PRL-3, a metastasis associated tyrosine phosphatase, is involved in
FLT3-ITD signaling and implicated in anti-AML therapy. PLoS ONE 6:
e19798
Research Article www.embomolmed.org
Oncogenic roles of PRL‐3 in AML
1366  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2013) 5, 1351–1366
